Kanghong Pharmaceutical wins approval for overactive bladder treatment

Chengdu Kanghong Pharmaceutical Group Co., Ltd. recently announced the receipt of a drug registration certificate from the National Medical Products Administration for Mirabegron extended-release tablets. This approval allows the company to market the drug as a Class 4 chemical medicine.

The approved drug, Mirabegron extended-release tablets (50mg), is indicated for the symptomatic treatment of urgency, frequency, and/or urge urinary incontinence in adult patients with overactive bladder (OAB). Mirabegron is a selective β3-adrenergic receptor agonist that relaxes the detrusor smooth muscle of the bladder.

The company anticipates that the launch of Mirabegron extended-release tablets will enrich its product portfolio. However, Kanghong Pharmaceutical also cautioned investors about potential uncertainties regarding the production and sales of pharmaceutical products, which may be influenced by national policies and market environment changes, advising prudence in investment decisions.